Meckler Jeffrey A
SEC CIK 1506916 · EDGAR
BoughtSold
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-11 16:05 | 2026-09-10 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | M - OptEx | $21.98 | +20.0K | 111.5K | +22% | +$439.6K |
| DMT | 2026-09-11 16:05 | 2026-09-10 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | S - Sale+OE | $67.31 | -20.0K | 91.5K | -18% | -$1.35M |
| D | 2026-05-21 17:00 | 2026-05-19 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | A - Grant | $0.00 | +4,000 | 91.5K | +5% | $0 |
| DT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | M - OptEx | $16.33 | +8,000 | 95.5K | +9% | +$130.6K |
| DT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | S - Sale+OE | $45.00 | -8,000 | 87.5K | -8% | -$360.0K |
| 2025-12-29 | 2025-12-22 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | Co-CEO, Dir, 10% | A - Grant | $2.03 | +216.6K | 229.9K | +1,627% | +$439.7K | |
| D | 2025-07-29 | 2025-07-27 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | A - Grant | $8.30 | +6,068 | 13.3K | +84% | +$50.4K |
| D | 2025-05-16 | 2025-05-15 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | A - Grant | $0.00 | +6,500 | 87.5K | +8% | $0 |
| D | 2024-11-26 | 2024-11-25 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | A - Grant | $1.18 | +42.6K | 202.9K | +27% | +$50.2K |
| D | 2024-09-30 | 2024-09-30 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | S - Sale+OE | $14.06 | -40.0K | 81.0K | -33% | -$562.4K |
| D | 2024-09-30 | 2024-09-30 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | M - OptEx | $10.48 | +40.0K | 121.0K | +49% | +$419.2K |
| D | 2024-08-08 | 2024-08-08 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | A - Grant | $1.83 | +84.9K | 160.3K | +113% | +$155.4K |
| D | 2024-05-10 | 2024-05-08 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | A - Grant | $0.00 | +6,500 | 81.0K | +9% | $0 |
| D | 2023-05-19 | 2023-05-17 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | A - Grant | $0.00 | +4,500 | 74.5K | +6% | $0 |
| M | 2022-11-22 | 2022-11-18+ | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $1.89 | +10.0K | 75.4K | +15% | +$18.9K |
| 2022-09-12 | 2022-09-08 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $2.80 | +10.3K | 65.4K | +19% | +$28.9K | |
| M | 2022-09-08 | 2022-09-06+ | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $2.56 | +9,692 | 55.1K | +21% | +$24.8K |
| 2022-06-07 | 2022-06-06 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $2.63 | +19.7K | 45.4K | +77% | +$51.9K | |
| D | 2022-05-12 | 2022-05-11 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | A - Grant | $0.00 | +3,000 | 70.0K | +4% | $0 |
| 2021-11-19 | 2021-11-18 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $5.82 | +11.2K | 25.6K | +77% | +$65.1K | |
| 2021-09-16 | 2021-09-14 | INDP | Indaptus Therapeutics, Inc. | Meckler Jeffrey A | CEO, Dir | P - Purchase | $7.00 | +12.0K | 14.5K | +488% | +$84.0K |
Purchase Sale Sale after option exercise All abbreviations